-
Trump says will fire Fed chair if he stays beyond mandate
-
Donors pledge 1.3 bn euros as Sudan marks three years of war
-
World Bank announces water security plan covering one billion people
-
Man Utd's Maguire out of Chelsea match after extra one-game ban
-
Oil rises, stocks mixed as investors eye chances for end of Mideast war
-
Doubles champion Jamie Murray retires from tennis
-
Merz praises Lufthansa on centenary as strikes ruin party
-
France's Gulf veteran minehunter patrols Channel
-
Brazil Supreme Court orders probe into Flavio Bolsonaro for 'slander' of Lula
-
IMF chief warns of 'tough times' if oil prices stay high
-
Bosnia approves gas project by Trump-linked investors
-
Pupil kills nine, wounds 13 in new Turkey school shooting
-
Left-wing candidate Sanchez climbs to second place in Peru vote count
-
New tools rescue old art at Madrid's Prado museum
-
Cameroonians welcome pope on second leg of African tour
-
Verstappen understands 'bigger picture' in power unit debate: F1 boss Domenicali
-
Hearn wants Katie Taylor to top Croke Park bill, rules out Fury-Joshua in Dublin
-
Stocks edge higher as investors eye chances for end of Mideast war
-
Iran ups threats over naval blockade, but still talking to US
-
Critically endangered orangutan born at Madrid zoo
-
EU rejects Meta's pay-for-access remedy in WhatsApp AI chatbots probe
-
Pupil kills four wounds 20 in new Turkey school shooting
-
Left-wing radical 'confident' after late surge in Peru presidential poll
-
Starmer says 'won't yield' to Trump's Mideast war threats
-
Liverpool captain Van Dijk says PSG 'deserved' Champions League semi-final spot
-
England women's rugby star Kildunne reveals body issues struggle
-
Chinese suppliers, Mideast importers fret about war fallout on trade
-
Markets steadier on Mideast peace hopes, as war hits luxury goods
-
EU says age-check app 'ready' in push to protect children online
-
New Hungarian leader Magyar says pro-Orban president must resign
-
After three years of war, Sudan confronts devastation as donors gather in Berlin
-
Pope heads to Cameroon with message of peace for conflict zone
-
OpenAI announces restricted-access cybersecurity model
-
England's Stokes 'quite lucky' to be alive after facial injury
-
Keiko Fujimori: Peru's biggest political loser inches toward victory
-
Barcelona hope young talent learn from Champions League disappointment
-
The Middle East war: latest developments
-
French luxury firms Hermes, Kering knocked by disappointing sales
-
Ukraine veteran stages puppet shows to honour killed soldiers
-
Afghans comb riverbed in search of gold dust
-
Stocks rally, oil falls further as Trump fans fresh peace hopes
-
Double Olympic badminton champion Axelsen announces retirement
-
Peru candidate demands vote annulment as count tightens
-
Tom Cruise shares sneak peek of Inarritu comedy 'Digger' at CinemaCon
-
Rosalia caps journey from student to star with Barcelona concerts
-
AI expansion drives up profits at bullish tech giant ASML
-
Hamano strikes as Japan end US winning streak
-
Xi meets Russian FM as leaders flock to China over Middle East war
-
'Industrial' clickbait disinformation targets Australian politics
-
AI-driven chip shortage slowing efforts to get world online: GSMA
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
O.Norris--AMWN